Berberine için Gut Dysbiosis
DPreclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
Sonuç
Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
Key Study Findings
In Vitro
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal …
Dose: None
vs: Sulfasalazine; DSS-induced UC mice
Outcome: UC treatment efficacy
Etki: Colon length 1.2x longer than sulfasalazine
None
Popülasyon: DSS-induced UC murine model
Review
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
Review
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver …
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None
vs: Free berberine; DSS-induced UC model vs normal mice
Outcome: DAI scores, inflammatory cytokines, gut microbiota
Etki: None
<0.01 (DAI); <0.05 (cytokines)
Popülasyon: DSS-induced UC mouse model (male KM mice)
Other
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
Dose: None
vs: DSS-induced colitis + periodontitis mouse models
Outcome: Periodontal destruction and myeloid cell generation
Etki: None
None
Popülasyon: DSS-induced colitis with periodontitis mouse model
Key Statistics
2
Çalışmalar
100
Katılımcılar
↑
Positive
D
Derece
Referenced Papers
International journal of …
2025
15 atıf
Colloids and surfaces. …
2025
11 atıf
Pharmaceuticals (Basel, Switzerland)
2025
8 atıf
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Review
Pharmaceuticals (Basel, Switzerland)
2025
8 atıf
Inflammatory bowel diseases
2025
2 atıf
Pharmaceutics
2025
2 atıf
Phytomedicine : international …
2025
2 atıf
The Journal of …
2025
1 atıf
European journal of …
2025
Archives of oral …
2025
Frontiers in nutrition
2025
Biomedicine & pharmacotherapy …
2024
17 atıf
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic Review
International journal of …
2024
14 atıf
Frontiers in pharmacology
2024
9 atıf
Hepatology communications
2024
9 atıf
Frontiers in microbiology
2024
6 atıf
Frontiers in microbiology
2024
5 atıf
Indian journal of …
2024
2 atıf
Gut microbes
2023
108 atıf
Biomedicine & pharmacotherapy …
2023
61 atıf
International journal of …
2023
48 atıf
Journal of ethnopharmacology
2023
29 atıf
Frontiers in pharmacology
2023
20 atıf
International journal of …
2023
18 atıf
Current pharmaceutical design
2023
10 atıf
Journal of oral …
2023
10 atıf
Journal of neurogastroenterology …
2023
4 atıf
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Review
Clinical and experimental …
2023
2 atıf
Microorganisms
2022
212 atıf
Food & function
2022
83 atıf
Phytomedicine : international …
2022
67 atıf
Biomaterials science
2022
34 atıf
Microbiology spectrum
2022
25 atıf
Brazilian journal of …
2022
12 atıf
Pharmacological research
2021
186 atıf
Pharmacological research
2021
147 atıf
Acta pharmacologica Sinica
2021
63 atıf
Frontiers in pharmacology
2021
42 atıf
Frontiers in immunology
2021
22 atıf
Comprehensive Physiology
2021
21 atıf
International journal of …
2021
20 atıf
Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Review
Pharmacological research
2020
65 atıf
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic Review
Journal of integrative …
2020
33 atıf
Pharmacological research
2019
166 atıf
American journal of …
2019
117 atıf
Biomedicine & pharmacotherapy …
2019
72 atıf
Scientific reports
2019
51 atıf
Pharmacological research
2019
31 atıf
Science China. Life …
2018
17 atıf
Alternative therapies in …
2017
9 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
Üst sınır: Generally well-tolerated up to 1,500 mg/day in divided doses
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 6 weeks | Positive | -- |
En iyi alım zamanı: With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
Bilinen Etkileşimler
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
Tolere edilebilir üst alım: Generally well-tolerated up to 1,500 mg/day in divided doses
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Gut Dysbiosis
Berberine diğer sağlık durumları için
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.